Low-dose olanzapine, sedation and chemotherapy-induced nausea and vomiting: a prospective randomized controlled study.
Sandip MukhopadhyayPremnath DuttaSanatan BanerjeeBiswamit BhattacharyaSupreeti BiswasRudolph M NavariPublished in: Future oncology (London, England) (2021)
Aims: Comparison of efficacy, safety and sedation between two doses of olanzapine in the control of chemotherapy-induced nausea and vomiting (CINV). Patients & methods: A prospective, randomized, double-blind, controlled study was conducted, enrolling 68 patients receiving a single-day cycle of high and moderately emetogenic chemotherapy. Patients received either of olanzapine 5 mg or 10 mg from day 1 through 3 in addition to ondansetron and dexamethasone. Control of CINV, nausea, sedation, quality of life (QoL) and adverse events were compared. Results: Nausea, emesis control and improvement of QoL were similar in both groups. Sedation severity was 133% higher with 10 mg olanzapine. Conclusions: Lower dose olanzapine is effective to control CINV with significantly reduced sedation.
Keyphrases
- chemotherapy induced
- end stage renal disease
- low dose
- ejection fraction
- chronic kidney disease
- newly diagnosed
- mechanical ventilation
- clinical trial
- peritoneal dialysis
- prognostic factors
- radiation therapy
- randomized controlled trial
- double blind
- patient reported outcomes
- acute respiratory distress syndrome
- extracorporeal membrane oxygenation
- clinical evaluation